These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 28967076)

  • 41. Comparison of Intravitreal Ranibizumab, Aflibercept, and Dexamethasone Implant after Bevacizumab Failure in Macular Edema Secondary to Retinal Vascular Occlusions.
    Hanhart J; Rozenman Y
    Ophthalmologica; 2017; 238(1-2):110-118. PubMed ID: 28535531
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective.
    Adedokun L; Burke C
    Adv Ther; 2016 Jan; 33(1):116-28. PubMed ID: 26747252
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.
    Kaldırım HE; Yazgan S
    Int Ophthalmol; 2018 Aug; 38(4):1549-1558. PubMed ID: 28646440
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Review of Randomized Trials of Approved Pharmaceutical Agents for Macular Edema Secondary to Retinal Vein Occlusion.
    Wang JK
    Asia Pac J Ophthalmol (Phila); 2016; 5(2):159-64. PubMed ID: 26692257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology.
    Yeh S; Kim SJ; Ho AC; Schoenberger SD; Bakri SJ; Ehlers JP; Thorne JE
    Ophthalmology; 2015 Apr; 122(4):769-78. PubMed ID: 25576994
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The VEGF Treatment of AMD Switch Study (The vTAS Study).
    Curry B; Bylsma G; Hewitt AW; Verma N
    Asia Pac J Ophthalmol (Phila); 2017; 6(6):481-487. PubMed ID: 29204996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative efficacy of bevacizumab, ranibizumab, and aflibercept for treatment of macular edema secondary to retinal vein occlusion: a systematic review and network meta-analysis.
    Sangroongruangsri S; Ratanapakorn T; Wu O; Anothaisintawee T; Chaikledkaew U
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):903-916. PubMed ID: 30071180
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravitreal anti-vascular endothelial growth factor therapy with bevacizumab for tuberous sclerosis with macular oedema.
    Saito W; Kase S; Ohgami K; Mori S; Ohno S
    Acta Ophthalmol; 2010 May; 88(3):377-80. PubMed ID: 18778334
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in flare after intravitreal injection of three different anti-vascular endothelial growth factor medications.
    Blaha GR; Brooks NO; Mackel CE; Pani A; Stewart AP; Price LL; Barouch FC; Chang J; Marx JL
    Retina; 2015 Mar; 35(3):577-81. PubMed ID: 25158942
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab.
    Narayan DS; Muecke J
    Indian J Ophthalmol; 2015 Nov; 63(11):832-6. PubMed ID: 26669334
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.
    Shah CP; Heier JS
    Ophthalmic Surg Lasers Imaging Retina; 2016 Sep; 47(9):836-9. PubMed ID: 27631479
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab.
    Konidaris V; Al-Hubeshy Z; Tsaousis KT; Gorgoli K; Banerjee S; Empeslidis T
    Int Ophthalmol; 2018 Feb; 38(1):207-213. PubMed ID: 28405787
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Are the real-life outcomes of using aflibercept in diabetic macular oedema comparable to the landmark studies?
    Higham AK; Tahir MI; Gala K; Verroiopoulos G
    Acta Ophthalmol; 2019 Mar; 97(2):e322-e323. PubMed ID: 30369094
    [No Abstract]   [Full Text] [Related]  

  • 54. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.
    Campochiaro PA; Clark WL; Boyer DS; Heier JS; Brown DM; Vitti R; Kazmi H; Berliner AJ; Erickson K; Chu KW; Soo Y; Cheng Y; Haller JA
    Ophthalmology; 2015 Mar; 122(3):538-44. PubMed ID: 25315663
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Three-month outcomes of ziv-aflibercept in the treatment of diabetic macular oedema.
    Ashraf M; Souka AA; El Kayal H; El Manhaly M; Abdallah MH
    Acta Ophthalmol; 2016 Nov; 94(7):e669. PubMed ID: 27227354
    [No Abstract]   [Full Text] [Related]  

  • 56. Pegaptanib sodium for acute retinal necrosis-induced macular oedema.
    Amselem L; Diaz-Llopis M; Cervera E; Salom D; Huste F; Montero J
    Acta Ophthalmol; 2010 Mar; 88(2):e42-3. PubMed ID: 18937824
    [No Abstract]   [Full Text] [Related]  

  • 57. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
    Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
    Wykoff CC; Hariprasad SM
    Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):302-5. PubMed ID: 25835307
    [No Abstract]   [Full Text] [Related]  

  • 59. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Trials in Branch Retinal Vein Occlusion.
    Panakanti TK; Chhablani J
    Middle East Afr J Ophthalmol; 2016; 23(1):38-43. PubMed ID: 26957837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.